Fluoroquinolone-induced serious, persistent, multisymptom adverse effects

Beatrice Alexandra Golomb1, Hayley Jean Koslik1, Alan J Redd2

  • 1Department of Medicine, University of California, San Diego, La Jolla, California, USA.

BMJ Case Reports
|October 7, 2015
PubMed

Insights

Fluoroquinolones (FQs) can cause severe, disabling symptoms like tendinopathy and neuropathy that persist after use. This mitochondrial toxicity may lead to a severe multisymptom condition.

Area of Science:

  • Pharmacology
  • Neurology
  • Toxicology

Background:

  • Fluoroquinolones (FQs) are broad-spectrum antibiotics.
  • Potential adverse effects of FQs are increasingly recognized.

Observation:

  • Four previously healthy adults developed severe, multisystem symptoms during or after FQ use.
  • Symptoms included tendinopathy, muscle weakness, neuropathy, autonomic dysfunction, sleep and cognitive disturbances, and psychiatric issues.

Findings:

  • Symptoms persisted and progressed even after FQ discontinuation.
  • The observed pathology aligns with FQ-induced delayed mitochondrial toxicity.
  • This suggests a potential mechanism for fluoroquinolone-induced mitochondrial neurogastrointestinal encephalomyopathy.

Implications:

  • Physicians and patients should be aware of the risk of severe, persistent FQ toxicity.
  • Early recognition and discontinuation of FQs may be crucial.
  • Further research into FQ-induced mitochondrial dysfunction is warranted.

Related Concept Videos

Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
51
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
95
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
107
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
1.1K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
878
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
350